Nasdaq:PALI
PALISADE BIO, INC.
A clinical-stage biotech firm developing next-generation immunotherapies for cancer treatment while operating with minimal current revenue.
Key Metrics
Investment Thesis
Bull Case
Investors might consider PALI if they believe the company's proprietary immunotherapy candidates have high potential for blockbuster approval and future market dominance upon commercialization. The company's focus on specific cancer indications addresses an unmet medical need with significant patient demand, offering a large addressable market upon product launch. Early-stage biotechs often experience exponential growth once a clinical milestone is achieved, potentially rewarding early adopters with substantial upside.
Bear Case
The stock carries extreme risk given the $135.9M retained earnings deficit and total liabilities exceeding equity, signaling potential solvency issues without further capital raises. With zero revenue across 2023 and 2024, the company lacks a proven track record of commercial success or sustainable profitability. Investors should avoid this stock if they require stable dividends or predictable cash flows, as the business model relies entirely on successful equity financing to survive.
About PALISADE BIO, INC.
PALISADE BIO, INC. (NASDAQ: PALI) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat cancer. The company primarily serves the oncology market with its proprietary drug candidates targeting specific immune checkpoints and tumor microenvironments. Currently in the research and development phase, the firm relies on strategic financing to fund its pipeline expansion and preclinical studies.
Analysis
Management Discussion
PALISADE BIO reported a net loss of $14.4M in 2024, maintaining a consistent pattern of high operating expenses driven by general and administrative costs totaling $5.8M and other operating expenses at $9.1M. The company generated zero revenue and zero cost of revenue, indicating it remains in the early research phase with no commercial products sold. Cash flow from operations was negative at $-12.2M, partially offset by $8.4M in common share issuances which helped replenish cash reserves.
Industry Overview
The global oncology sector is highly competitive with numerous large pharmaceutical companies and smaller biotech firms vying for approval of novel therapies. Biotechnology companies in this space typically face long development cycles requiring billions of dollars before generating any commercial revenue. Regulatory hurdles from the FDA are stringent, and only a fraction of clinical candidates succeed in reaching market.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $250.0K | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $250.0K | $0 |
| Operating Expenses | $15.7M | $13.3M | $14.9M |
| Operating Income | $-15.7M | $-13.1M | $-14.9M |
| G&A | $8.8M | $6.2M | $5.8M |
| Stock-Based Comp | $1.0M | $624.0K | $652.0K |
| D&A | $3.0K | — | — |
| Depreciation | — | $4.0K | $3.0K |
| Other OpEx | $7.0M | $7.1M | $9.1M |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Expense | $13.0K | $15.0K | $12.0K |
| Pre-Tax Income | $-15.7M | $-13.1M | $-14.9M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-15.7M | $-13.1M | $-14.9M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-14.3M | $-12.3M | $-14.4M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-14.3M | $-12.3M | $-14.4M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $14.7M | $13.3M | $10.5M |
| Cash & Equivalents | $12.4M | $12.4M | $9.8M |
| Prepaid Expenses | $2.4M | $896.0K | $673.0K |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $1.0M | $724.0K | $386.0K |
| PP&E (Net) | $10.0K | $10.0K | $3.0K |
| Operating Leases | $300.0K | $198.0K | $84.0K |
| Other LT Assets | $720.0K | $516.0K | $299.0K |
| Total Assets | $15.8M | $14.1M | $10.9M |
| Current Liabilities | $3.0M | $2.6M | $3.2M |
| Accounts Payable | $1.8M | $698.0K | $1.1M |
| Current Leases | $105.0K | $121.0K | $90.0K |
| Other Current Liab | $574.0K | $936.0K | $801.0K |
| Long-Term Liabilities | $272.0K | $153.0K | $152.0K |
| LT Operating Leases | $211.0K | $90.0K | $0 |
| Other LT Liab | $61.0K | $63.0K | $152.0K |
| Total Liabilities | $3.3M | $2.7M | $3.4M |
| Shareholders' Equity | $12.5M | $11.3M | $7.5M |
| Paid-In Capital | $121.6M | $132.7M | $143.4M |
| Retained Earnings | $109.2M | $121.5M | $135.9M |
| Total L&E | $15.8M | $14.1M | $10.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-14.3M | $-12.3M | $-14.4M |
| Non-Cash Adjustments | $1.5M | $2.1M | $2.4M |
| Working Capital Changes | $-571.0K | $-902.0K | $-109.0K |
| Cash from Operations | $-13.4M | $-11.1M | $-12.2M |
| Capital Expenditures | $10.0K | $4.0K | $0 |
| Cash from Investing | $-10.0K | $-4.0K | $0 |
| Cash from Financing | $15.3M | $11.2M | $9.6M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $1.9M | $49.0K | $-2.6M |
| Beginning Cash | $10.5M | $12.4M | $12.5M |
| Ending Cash | $12.4M | $12.5M | $9.8M |
Frequently Asked Questions
How does PALISADE BIO, INC. make money?
The company's operations are currently concentrated in a single core segment: Oncology Immunotherapy R&D, which encompasses all drug discovery, preclinical development, and early clinical trial activities. Due to the lack of commercial sales data, there are no distinct product-based revenue streams or licensing income reported in the financial statements.
What are the main risks for PALI?
The company faces significant financial risk due to substantial operating losses of $14.4M in 2024 and a complete lack of commercial revenue streams. As a pre-revenue entity, PALI is entirely dependent on successful fundraising events like common share issuances to sustain cash reserves, which decreased by $2.6M recently. There is no guarantee that any drug candidates will successfully advance through clinical trials or receive regulatory approval from the FDA. High dilution risk remains elevated as the company issues equity frequently to cover cash burn.
What is PALI's competitive advantage?
The firm leverages proprietary antibody-drug conjugate (ADC) technology platforms that offer enhanced targeting precision compared to traditional immunotherapies. Strategic partnerships with academic institutions provide access to novel target identification and early-stage discovery resources. The lean organizational structure allows for agile decision-making in the fast-paced biotechnology sector.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.